IPA chairman Samir Mehta says manufacturers of scheduled medicines are facing viability issues due to high supply chain, logistics costs

Mehta batted for a market friendly pricing structure which will help in accessibility of medicines to the patients and increase investment in research and overall export thrust in global market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m2OiMqu
via IFTTT